Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in ApcMin/+ Mice.

BACKGROUND Recent epidemiological and experimental studies have shown that obesity is a major risk factor for Colorectal Cancer (CRC). Regular intake of high fat-containing diet can promote obesity and metabolic syndrome by increasing the insulin resistance and inflammatory response which contribute to carcinogenesis. Previously, we have shown that inhibition of polyol pathway enzyme aldose reductase (AR) prevents carcinogens- and inflammatory growth factorsinduced CRC. However, the effect of AR inhibition on a high-fat diet (HFD)-induced formation of intestinal polyps in Apc-deficient Min (multiple intestinal neoplasia; ApcMin/+) mice is not known. METHODS We examined the effect of AR inhibitor, fidarestat on the HFD-induced formation of preneoplastic intestinal polyps in ApcMin/+ mice which is an excellent model of colon cancer. RESULTS APCMin/+ mice fed for 12 weeks of HFD caused a significant increase in the formation of polyps in the small and large intestines and fidarestat given along with the HFD prevented the number of intestinal polyps. Fidarestat also decreased the size of the polyps in the intestines of HFDtreated APC Min mice. Further, the expression levels of beta-catenin, PCNA, PKC-β2, P-AKT, Pp65, COX-2, and iNOS in the small and large intestines of HFD-treated mice significantly increased, and AR inhibitor prevented it. CONCLUSION Our results thus suggest that fidarestat could be used as a potential chemopreventive drug for intestinal cancers due to APC gene mutations.

[1]  Zu-hua Gao,et al.  Chemoprevention of intestinal tumorigenesis by the natural dietary flavonoid myricetin in APCMin/+ mice , 2016, Oncotarget.

[2]  Xian-Jun Qu,et al.  Naringin, a natural dietary compound, prevents intestinal tumorigenesis in ApcMin/+ mouse model , 2016, Journal of Cancer Research and Clinical Oncology.

[3]  Xu-Feng Huang,et al.  Bardoxolone Methyl Prevents High-Fat Diet-Induced Colon Inflammation in Mice , 2016, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[4]  K. Ramana,et al.  Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. , 2014, Cancer letters.

[5]  K. Ramana,et al.  Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression. , 2013, European journal of cancer.

[6]  J. Schmid,et al.  The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.

[7]  Ashish Saxena,et al.  Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a. , 2013, Antioxidants & redox signaling.

[8]  L. Malkas,et al.  Small-Molecule Targeting of Proliferating Cell Nuclear Antigen Chromatin Association Inhibits Tumor Cell Growth , 2012, Molecular Pharmacology.

[9]  K. Ramana,et al.  Inhibition of aldose reductase prevents colon cancer metastasis. , 2011, Carcinogenesis.

[10]  K. Ramana,et al.  Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. , 2011, Chemico-biological interactions.

[11]  Ashish Saxena,et al.  Aldose Reductase Inhibition Prevents Hypoxia-induced Increase in Hypoxia-inducible Factor-1α (HIF-1α) and Vascular Endothelial Growth Factor (VEGF) by Regulating 26 S Proteasome-mediated Protein Degradation in Human Colon Cancer Cells* , 2011, The Journal of Biological Chemistry.

[12]  J. Davis,et al.  Quercetin's Effects on Intestinal Polyp Multiplicity and Macrophage Number in the Apc Min/+ Mouse , 2011, Nutrition and cancer.

[13]  W. Ladiges,et al.  Curcumin suppresses intestinal polyps in APC Min mice fed a high fat diet , 2011, Pathobiology of aging & age related diseases.

[14]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[15]  R. Agarwal,et al.  Silibinin Suppresses Spontaneous Tumorigenesis in APCmin/+ Mouse Model by Modulating Beta-Catenin Pathway , 2009, Pharmaceutical Research.

[16]  K. Ramana,et al.  Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. , 2009, Carcinogenesis.

[17]  N. Vickaryous,et al.  Apc mice: models, modifiers and mutants. , 2008, Pathology, research and practice.

[18]  E. Giovannucci,et al.  The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. , 2007, Gastroenterology.

[19]  H. Mori,et al.  Multistep carcinogenesis of the colon in ApcMin/+ mouse , 2007, Cancer science.

[20]  K. Ramana,et al.  Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. , 2006, Cancer research.

[21]  Huiying Luo,et al.  Expression of survivin and correlation with PCNA in osteosarcoma , 2006, Journal of surgical oncology.

[22]  T. Sugimura,et al.  Inhibition of intestinal carcinogenesis by a new flavone derivative, chafuroside, in oolong tea , 2006, Cancer science.

[23]  E. Ho,et al.  Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice , 2006 .

[24]  W. Shih,et al.  Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. , 2005, Cancer research.

[25]  M. Chiriva-Internati,et al.  Influence of obesity on the risk of developing colon cancer , 2005, Gut.

[26]  Charis Eng,et al.  Highly penetrant hereditary cancer syndromes , 2004, Oncogene.

[27]  C. Ulrich,et al.  Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients , 2003, Diabetologia.

[28]  Ricky A. Sharma,et al.  Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  A. Fields,et al.  Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. , 2001, Cancer research.

[30]  T. Sugimura,et al.  Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. , 2000, Carcinogenesis.

[31]  M. Bertagnolli,et al.  Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. , 2000, Carcinogenesis.

[32]  L. Howells,et al.  Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex , 1999, Oncogene.

[33]  A. Fields,et al.  Overexpression of Protein Kinase C βII Induces Colonic Hyperproliferation and Increased Sensitivity to Colon Carcinogenesis , 1999, The Journal of cell biology.

[34]  Margaret Robertson,et al.  Identification and characterization of the familial adenomatous polyposis coli gene , 1991, Cell.

[35]  K. Kinzler,et al.  Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. , 1991, Science.

[36]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[37]  A. Francavilla,et al.  n-3 polyunsaturated fatty acids reverse the development of polyps in Apc(Min/+) transgenic mice. , 2016, Oncology reports.

[38]  Lawrence N Kwong,et al.  APC and its modifiers in colon cancer. , 2009, Advances in experimental medicine and biology.

[39]  K. Kashfi,et al.  Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Rao,et al.  Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. , 2002, Cancer research.

[41]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.

[42]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.